A new compound, discovered jointly by international pharmaceutical company Servier, headquartered in France, and Vernalis (R&D), a company based in the UK, has been shown by researchers at the Walter and Eliza Hall Institute and Servier to block a protein that is essential for the sustained growth of up to a quarter of all cancers.
The research presents a new way to efficiently kill these cancerous cells and holds promise for the treatment of blood cancers such as acute myeloid leukaemia,lymphoma and multiple myeloma, as well as solid cancers such as melanoma and cancers of the lung and breast. It is published online today in the journal Nature.
The Servier compound – S63845 – targets a protein of the BCL2 family, called MCL1, which is essential for the sustained survival of these cancer cells.
Institute scientist Associate Professor Guillaume Lessene, who led the Walter and Eliza Hall Institute’s research team in Melbourne, Australia, said the work provided the first clear preclinical evidence that inhibiting MCL1 was effective in targeting several cancer types.
“MCL1 is important for many cancers because it is a pro-survival protein that allows the cancerous cells to evade the process of programmed cell death that normally removes cancer cells from the body,” Associate Professor Lessene said. “Extensive studies performed in a variety of cancer models have shown that S63845 potently targets cancer cells dependent on MCL1 for their survival.”
The institute team of Associate Professor Lessene worked with haematologist Associate Professor Andrew Wei and Dr Donia Moujalled from The Alfred Hospital and Servier scientists, to demonstrate that not only was S63845 effective against several cancer types, but that it could also be delivered at doses that were well tolerated by normal cells.
Dr Olivier Geneste, Director of Oncology Research at Servier, said this preclinical research represented major findings regarding the druggability of MCL1, a valuable and highly challenging target. “S63845 was discovered through collaboration with the fragment and structure based discovery expertise at Vernalis,” he said. “As part of the ongoing Servier / Novartis collaboration on this target class, clinical development of a MCL1 inhibitor should be launched in the near future.”
Associate Professor Lessene said the research provided further evidence of the usefulness of a new class of anti-cancer drugs called BH3 mimetics. “BH3 mimetics inhibit a group of proteins known as the ‘pro-survival BCL-2 proteins’,” he said. “MCL1 is a member of this protein family, and inhibiting it activates the process of programmed cell death. Walter and Eliza Hall Institute researchers revealed the role of BCL-2 in cancer more than 28 years ago and the essential role of MCL1 for the survival of malignant cells four years ago.”
The Latest on: Cancer treatment
via Google News
The Latest on: Cancer treatment
- Early marker of cardiac damage triggered by cancer treatment identified on February 18, 2019 at 11:47 pm
The results, published in JACC, have implications for patient prognosis, since detection of this marker can prompt intervention to prevent irreversible damage Every year, 4 million new cases of cancer ... […]
- When Cancer Treatment Takes Away Your Sexual Desire on February 18, 2019 at 5:47 pm
Sex is everywhere: on television, newsstands, talk shows, the radio, billboards, the books we read and of course, the internet. Where it does not seem to exist is in the bedrooms of those of us being ... […]
- A community of caring: Ethan native undergoes intensive cancer treatment on February 18, 2019 at 3:23 pm
ETHAN—Last year, after seeing a doctor about his nosebleeds, headaches and watery eyes, Tanner Riggs was told he probably just had a sinus infection. Following intensive chemotherapy, a major surgery ... […]
- Very early marker of cardiac damage triggered by cancer treatment on February 18, 2019 at 3:05 pm
Researchers have identified a very early marker of cardiac damage in patients undergoing therapy with anthracyclines, a family of drugs commonly used to treat cancer. This finding will enable the earl... […]
- Dr. Ranganath on Treatment Considerations in Nonmetastatic Prostate Cancer on February 18, 2019 at 3:02 pm
Harsha Ranganath, MD, a fellow in the Division of Hematology & Oncology at the University of Tennessee West Cancer Center, discusses treatment considerations in nonmetastatic prostate cancer. Patients ... […]
- CNIC researchers identify a very early marker of cardiac damage triggered by cancer treatment on February 18, 2019 at 11:05 am
Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.) Every year, 4 million new cases of cancer are diagnosed in Europe. Advances in cancer treatment sometimes come at the cost of ma... […]
- Certain Factors Impact Treatment Selection in Advanced Prostate Cancer on February 18, 2019 at 7:31 am
A patient’s race, income level, geographic area of residence, and whether management is conducted by a medical oncologist or a urologist may significantly influence the type of treatment administered ... […]
- New nanomedicines for a more efficient and less aggressive treatment of prostate cancer on February 18, 2019 at 6:03 am
In Europe, prostate cancer is the most common type of cancer among men with an incidence greater than 100 cases per 100,000 individuals. Furthermore, it is currently the second most common cause ... […]
- Researchers identify protein that contributes to racial disparities in prostate cancer on February 18, 2019 at 5:06 am
Cancer researchers have long known that prostate cancer tends to be more common, more aggressive and more resistant to existing treatments in African-Americans than in Caucasian-Americans ... […]
via Bing News